Frontage Holdings Corporation is a global pharmaceutical development organization that provides integrated laboratory and clinical services for drug discovery and development. The company operates as a full-service contract research organization (CRO) and contract development and manufacturing organization (CDMO), offering a comprehensive portfolio of services including drug discovery, drug metabolism and pharmacokinetics (DMPK), safety and toxicology, bioanalytical testing, and chemistry, manufacturing, and controls (CMC). Frontage supports clients in advancing drug candidates from lead optimization through first-in-human studies and IND submissions, serving pharmaceutical, biotechnology, and agrochemical companies. Its CMC capabilities cover API synthesis, formulation, and clinical trial material manufacturing for new chemical entities, 505(b)(2), and ANDA products, including biologics and cell and gene therapies. The company serves markets in North America, Europe, and Asia Pacific, with sites in the United States, China, and other regions. Frontage Laboratories, Inc. is a principal subsidiary, and the group has acquired entities such as Nucro-Technics Inc. and Accelera S.r.l. to expand its bioanalytical and testing capabilities.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Diagnostics & Research Homepage frontagelab.com
Sector Healthcare IR page frontagelab.com/investor-relations
Tags
drug discovery, drug development, contract research organization, contract development and manufacturing organization, pharmacokinetics, toxicology, bioanalytical testing, chemistry manufacturing and controls, clinical trial services, agrochemical testing, biologics, cell and gene therapy, Frontage Laboratories Inc., Nucro-Technics Inc., Nucro-Technics Holdings, Accelera S.r.l.
Press page —

Metrics

Valuation  
Market cap HK$ 4.21B
Market cap (USD) $ 536.529M
P/E 78.11
PEG —
P/BV 1.50
P/S 1.93
P/OCF 10.56
P/FCF —
Dividend yield —
Turnover / mcap 0.03%
Returns  
ROE 2.0%
ROI 1.7%
ROIC 1.7%
Profit margin 2.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -35.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 26.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 256.691M 254.907M 259.855M 250.36M 184.441M 125.811M 100.415M 83.114M
Net profit 6.793M 791K 10.808M 25.735M 18.428M 17.15M 18.424M 11.241M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 0.23 0.23 0.27 0.29 0.51 0.65 0.41 —
Price performance 12m 0 -0.16 -0.07 -0.43 -0.21 0.58 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Frontage Holdings Corporation (ticker 1521), listed in Hong Kong.

ETFs Holding Frontage Holdings Corporation

ETF Weight in ETF Shares Market value As of
DFIS 0.00% 162,000 $ 43.057K Nov 12, 2026
DISV 0.00% 26,000 $ 6,910.44 Nov 12, 2026